[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574689":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":52,"collaborators":54,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-007","ACTIVE_COMPARATOR","Topical DA-007 Solution",[13],"Drug: DA-007",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Topical Placebo Solution",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Topical placebo solution",[15],[30],{"name":31,"affiliation":32,"role":33},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",[40],{"facility":41,"status":25,"city":42,"state":25,"zip":25,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Rome (\"G. Marconi\")","Rome","Italy",{"type":45,"coordinates":46},"Point",[47,48],12.51133,41.89193,{"lat":48,"lon":47},[51],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"type":53,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[55,57],{"name":56,"class":6},"Daniel Alain, Inc.",{"name":58,"class":6},"Follea International Limited","100574689",false,"NCT06762548","Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","18 Years","65 Years",{"count":68,"type":69},140,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia",[75,76],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[75,78],"Chemotherapy Alopecia","NOT_YET_RECRUITING","2025-05-22",{"date":82,"type":83},"2025-05-23","ACTUAL",{"date":85,"type":69},"2025-10-10",{"date":87,"type":69},"2026-11-06",{"name":5,"class":6},1]